MTP - Midatech MTX110 shows encouraging action in early stage of fatal childhood brain cancer

Midatech Pharma (MTP) +37% premarket on announcing positive initial data from Phase I study of MTX110, an investigational nano-inclusion product, for the treatment of the fatal childhood brain cancer at the University of California, San Francisco in patients with Diffuse Intrinsic Pontine Glioma ((DPIG)).The primary endpoint was to evaluate the safety and efficacy of MTX110 in total 7 patients with DIPG recruited into the UCSF study. The patients, recently analyzed with DIPG and received focal external beam radiation therapy four to 14 weeks before commencement of MTX110 treatment. Qualification required a pontine area of the tumor with diffuse association of at slightest two thirds of the pons and no prove of metastatic illness. Patients were not prohibited by add up to tumor volume.Patients got up to 12 cycles of treatment each four to eight weeks. The measurements was raised between and inside patients as endured at first by expanding the mixture volume at a concentration of 30?M MTX110

For further details see:

Midatech MTX110 shows encouraging action in early stage of fatal childhood brain cancer